EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer
Journal of Clinical Investigation · 03.04.2023 · 133 (7)
DOI: 10.1172/jci165863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, erschienen am 03.04.2023. Verfasst von Xiaochao Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Lung Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Lung Cancer Research Foundation.
Abstract (Originalsprache)
Hypersecretory malignant cells underlie therapeutic resistance, metastasis, and poor clinical outcomes. However, the molecular basis for malignant hypersecretion remains obscure. Here, we showed that epithelial-mesenchymal transition (EMT) initiates exocytic and endocytic vesicular trafficking programs in lung cancer. The EMT-activating transcription factor zinc finger E-box-binding homeobox 1 (ZEB1) executed a PI4KIIIβ-to-PI4KIIα (PI4K2A) dependency switch that drove PI4P synthesis in the Golgi and endosomes. EMT enhanced the vulnerability of lung cancer cells to PI4K2A small-molecule antagonists. PI4K2A formed a MYOIIA-containing protein complex that facilitated secretory vesicle biogenesis in the Golgi, thereby establishing a hypersecretory state involving osteopontin (SPP1) and other prometastatic ligands. In the endosomal compartment, PI4K2A accelerated recycling of SPP1 receptors to complete an SPP1-dependent autocrine loop and interacted with HSP90 to prevent lysosomal degradation of AXL receptor tyrosine kinase, a driver of cell migration. These results show that EMT coordinates exocytic and endocytic vesicular trafficking to establish a therapeutically actionable hypersecretory state that drives lung cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.
- Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA.
- Department of Medicine and Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
- Department of Bioinformatics and Computational Biology, The University of Texas-MD Anderson Cancer Center, Houston, Texas, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health
- Lung Cancer Research Foundation
Zitieren
APA
Tan, X., Xiao, G. Y., Wang, S., Shi, L., Zhao, Y., Liu, X., Yu, J., Russell, W. K., Creighton, C. J., & Kurie, J. M. (2023). EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci165863
Vancouver
Tan X, Xiao GY, Wang S, Shi L, Zhao Y, Liu X, et al. EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer. Journal of Clinical Investigation. 2023. doi:10.1172/jci165863
BibTeX
@article{Tan2023,
author = {Tan, Xiaochao and Xiao, Guan-Yu and Wang, Shike and Shi, Lei and Zhao, Yanbin and Liu, Xin and Yu, Jiang and Russell, William K and Creighton, Chad J and Kurie, Jonathan M},
title = {EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer},
journal = {Journal of Clinical Investigation},
year = {2023},
doi = {10.1172/jci165863}
}
EUVIMED